Docetaxel: all 1,319 studies that test it
Page 7 of 14. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.
- Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT02786641Phase 3
- Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung CancerStatus unknownNCT02780778Phase 2/3
- Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland CarcinomasCompletedNCT02776163Phase 2
- Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and NeckCompletedNCT02776137Phase 2
- SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung CancerTerminatedNCT02766140Phase 3
- Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck CancerActive, not recruitingNCT02760667Phase 2
- Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant ChemotherapyStatus unknownNCT02753140Phase 2
- Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal CancerCompletedNCT02725424Phase 2
- Phase II Trial for the Treatment of Relapsed OsteosarcomaTerminatedNCT02718482Phase 2
- Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical CancerStatus unknownNCT02703961Phase 3
- Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFRStatus unknownNCT02691871Phase 1
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
- Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric CancerStatus unknownNCT02623153Phase 2
- Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal CarcinomaStatus unknownNCT02621970Phase 3
- Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal CarcinomaStatus unknownNCT02610556Phase 2
- Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by SurgeryWithdrawnNCT02607423Phase 2
- Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1
- Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung CancerStatus unknownNCT02568033Early Phase 1
- Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck CancerStatus unknownNCT02567383Phase 2
- Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung CancerWithdrawnNCT02536495Phase 1/2
- Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung CancerCompletedNCT02531737Phase 2
- Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) CancerStatus unknownNCT02512380Phase 3
- A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal CarcinomaStatus unknownNCT02512315Phase 3
- Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the EsophagusActive, not recruitingNCT02509286Phase 3
- WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and NeckCompletedNCT02508246Phase 1
- A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast CancerCompletedNCT02488564Phase 2
- Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) TherapyCompletedNCT02484677Phase 4
- Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate CancerTerminatedNCT02478125Phase 1
- Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)Active, not recruitingNCT02465736Phase 3
- Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung CancerTerminatedNCT02460367Phase 1
- Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung CancerWithdrawnNCT02451865Phase 1
- Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line ChemotherapyCompletedNCT02448290Phase 2
- Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line TreatmentCompletedNCT02447406Phase 1/2
- Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line TreatmentCompletedNCT02447380Phase 2
- Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial CancerCompletedNCT02437370Phase 1
- Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal CancerCompletedNCT02403531Phase 2
- Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal CarcinomaCompletedNCT02402842Phase 2
- Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast CancerCompletedNCT02402712Phase 3
- Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric CancerStatus unknownNCT02378389Phase 1
- Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast CancerCompletedNCT02365805Phase 2
- Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal CarcinomaCompletedNCT02360501Phase 2
- Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast CancerCompletedNCT02324088Phase 3
- Dose-dense Biweekly Docetaxel, Oxaliplatin and 5-fluorouracil as First-line Treatment in Advanced Gastric CancerStatus unknownNCT02289378Phase 2
- Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid CancerCompletedNCT02274610Phase 1
- Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCCCompletedNCT02268695Phase 2
- Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerTerminatedNCT02257619Phase 2
- A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric CancerCompletedNCT02252913Phase 1
- Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung CancerCompletedNCT02225405Phase 1
- A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained TherapyCompletedNCT02223884Phase 2
- Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction ChemotherapyCompletedNCT02216617Phase 1
- Molecular Phenotype Changes and Personalized Treatment for CRPCStatus unknownNCT02208583Not applicable
- Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung CancerStatus unknownNCT02191059Phase 2
- LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After DocetaxelWithdrawnNCT02182622Phase 1
- Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLCTerminatedNCT02179567Phase 2
- Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric AdenocarcinomaStatus unknownNCT02177552Phase 2
- Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171741Phase 1
- BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171676Phase 1
- VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid TumorsCompletedNCT02146222Phase 1
- Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung CancerStatus unknownNCT02134990Phase 2
- Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid TumorsWithdrawnNCT02120118Phase 2
- 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEFCompletedNCT02115204Phase 3
- Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and NeckTerminatedNCT02110992Phase 1
- A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced OsteosarcomaStatus unknownNCT02099396Phase 2/3
- Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable PatientsStatus unknownNCT02099188Phase 2
- Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable PatientsStatus unknownNCT02099175Phase 2
- LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian CarcinomaWithdrawnNCT02083536Phase 1
- Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric CancerTerminatedNCT02076594Phase 3
- The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）Status unknownNCT02076477Phase 3
- SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHNCompletedNCT02057107Phase 2
- Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCCCompletedNCT02047201Phase 2
- Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate CancerCompletedNCT02044354Phase 3
- Biweekly Docetaxel in Patients With Metastatic Breast Cancer.CompletedNCT02041351Phase 2
- Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung caStatus unknownNCT02036359Phase 2
- Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.CompletedNCT02036060Phase 2
- Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02035527Phase 1
- Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung CancerStatus unknownNCT02031601Phase 4
- A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian CancerCompletedNCT02026921Phase 2
- MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric CancerStatus unknownNCT02007148Phase 2
- Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric CancerCompletedNCT02004769Phase 2
- Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠBStatus unknownNCT02001168Phase 3
- Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical CancerStatus unknownNCT01999933Phase 2/3
- Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast CancerTerminatedNCT01985841Phase 2
- A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric CancerTerminatedNCT01967875Phase 2
- A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGCStatus unknownNCT01963702Phase 2
- A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLCCompletedNCT01957007Phase 1
- Docetaxel and Lycopene in Metastatic Prostate CancerCompletedNCT01949519Phase 1
- Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung CancerWithdrawnNCT01938456Phase 1
- Dovitinib Plus Docetaxel in Gastric CancerCompletedNCT01921673Phase 1/2
- Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell CancerCompletedNCT01914900Phase 2
- Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid TumorsCompletedNCT01907685Phase 1
- A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast CancerStatus unknownNCT01907529Phase 2/3
- Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial CarcinomaWithdrawnNCT01907308Phase 2
- Molecularly Tailored Therapy for Pancreas CancerCompletedNCT01888978Phase 2
- A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung CancerCompletedNCT01862081Phase 1
- Phase I Study of LB-100 With Docetaxel in Solid TumorsCompletedNCT01837667Phase 1
- A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric CancerStatus unknownNCT01836120Phase 2
- Endostar + GT in Pulmonary Metastases of Soft Tissue SarcomaStatus unknownNCT01812018Phase 2
- Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerSuspendedNCT01810913Phase 2/3
- Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast CancerCompletedNCT01792050Phase 2
- ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerCompletedNCT01779206Phase 2/3